Dr Reddy’s Laboratories has moved higher by nearly 2% at Rs 2,828, also its record high on the NSE, after the company said it has launched Sumatriptan Injection USP in the US.
The injection is an autoinjector system for subcutaneous use. It is a therapeutic equivalent generic version of Imitrex Statdose Pen (sumatriptan succinate) and was launched in the US market on Tuesday following approval by the United States Food & Drug Administration (USFDA), Dr Reddy’s said in a press release.
The stock opened at Rs 2,785 and touched a low of Rs 2,784 on the NSE. A combined around 48,000 shares changed hands on the counter so far on the BSE and NSE.
The injection is an autoinjector system for subcutaneous use. It is a therapeutic equivalent generic version of Imitrex Statdose Pen (sumatriptan succinate) and was launched in the US market on Tuesday following approval by the United States Food & Drug Administration (USFDA), Dr Reddy’s said in a press release.
The stock opened at Rs 2,785 and touched a low of Rs 2,784 on the NSE. A combined around 48,000 shares changed hands on the counter so far on the BSE and NSE.
